Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alberta Warner

Cardiovascular Disease Los Angeles, CA Medical Doctor

NPI 1255443578 CMS profile 427761

11301 Wilshire Blvd, Cardiology 111E, Los Angeles, CA 90073

Open in the dashboard

General payments

$12,062

26 records reported · program years 2019–2025

Research payments

$1,138

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$162,219 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Alberta Warner of Los Angeles, CA is reported in the CMS Open Payments database as having received $12,062 across 26 general payments and $1,138 in research payments paid to them. Separately, studies naming them as principal investigator received $162,219 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,158 6
2024 General $76 1
2023 General $334 5
2022 General $396 5
2021 General $40 1
2019 General $5,058 8
2019 Research $1,138 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alberta Warner
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Alberta Warner were reported at $6,158. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Alberta Warner Cardiovascular Disease median Middle half National median
2019 $5,058 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $40 $335 $101–$1,037 $132
2022 $396 $395 $121–$1,211 $149
2023 $334 $443 $136–$1,283 $160
2024 $76 $450 $136–$1,323 $164
2025 $6,158 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $11,012 10 payments
  2. Alnylam Pharmaceuticals Inc. $286 4 payments
  3. E.R. Squibb & Sons, L.L.C. $270 3 payments
  4. Edwards Lifesciences Corporation $199 2 payments
  5. Impulse Dynamics (USA) Inc. $103 1 payment
  6. Abbott Laboratories $50 1 payment
  7. AstraZeneca Pharmaceuticals LP $44 1 payment
  8. Daiichi Sankyo Inc. $43 1 payment
  9. W. L. Gore & Associates, Inc. $23 1 payment
  10. Bardy Diagnostics, Inc. $18 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,000 2 payments
  2. Travel and Lodging $4,584 3 payments
  3. Food and Beverage $1,432 18 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40 1 payment
  5. Education $7 2 payments
Products named General payments · program years 2019–2025
  1. VYNDAQEL $6,065 5 payments
  2. CAMZYOS $270 3 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $198 1 payment
  4. ONPATTRO $116 1 payment
  5. OPTIMIZER Cardiovascular Device $103 1 payment
  6. OPTIMIZER Cardiovascular Device $103 1 payment
  7. AMVUTTRA $76 1 payment
  8. CARDIOMEMS $50 1 payment
  9. WAINUA $44 1 payment
  10. INJECTAFER $43 1 payment
  11. Other $97 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. United Therapeutics Corporation $1,138 4 payments

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record